Press Release

Company Profile for NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently conducting two Phase 3 registration studies. Teduglutide, a proprietary analog of GLP-2 is being evaluated as GATTEX(TM) in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and in preclinical development for gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Kirin, Nycomed, and Ortho-McNeil. Additional information is available at http://www.npsp.com.

Company:		NPS Pharmaceuticals

Headquarters Address:		550 Hills Drive
		Third Floor
		Bedminster, NJ 07921

Main Telephone:		908-450-5300

Website:		www.npsp.com

Ticker/ISIN:		NPSP(NASDAQ)/US62936P1030

Type of Organization:		Public
		PR

Industry:		Biotechnology

Key Executives:		CEO: Francois Nader
		CFO: Luke Beshar
		CMO: Roger Garceau

Investor Relations
Contact:		Susan Mesco
Phone:		908-450-5300
Email:		smesco@npsp.com

Investor Relations
Contact:		Gail Brophy
Phone:		908-450-5300
Email:		gbrophy@npsp.com

Source: NPS Pharmaceuticals

The reports filed by NPS with the Securities and Exchange Commission and the news releases issued by NPS and posted on this website are current only as of the dates on which they were filed or issued by NPS. Therefore, the contents of these reports and releases can become outdated. We make no commitment, and disclaim any duty, to update these reports and releases. We do not warrant the accuracy or completeness of these materials or the reliability of any advice, opinion, statement or other information displayed or distributed through the website. Readers acknowledge that any reliance on these reports, releases, advice, opinions, statements, or information are at the reader’s sole risk.

Return to Press Release Archives »